{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:02:02Z","timestamp":1772136122434,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Rejection after kidney transplantation remains an important cause of allograft failure that markedly impacts morbidity. Cytokines are a major player in rejection, and we, therefore, explored the impact of interleukin-6 (\n                    <jats:italic>IL6<\/jats:italic>\n                    ) and IL-6 receptor (\n                    <jats:italic>IL6R<\/jats:italic>\n                    ) gene polymorphisms on the occurrence of rejection after renal transplantation. We performed an observational cohort study analyzing both donor and recipient DNA in 1271 renal transplant\u2010pairs from the University Medical Center Groningen in The Netherlands and associated single nucleotide polymorphisms (SNPs) with biopsy-proven rejection after kidney transplantation. The C-allele of the\n                    <jats:italic>IL6R<\/jats:italic>\n                    SNP (Asp358Ala; rs2228145 A\u2009&gt;\u2009C, formerly rs8192284) in donor kidneys conferred a reduced risk of rejection following renal transplantation (HR 0.78 per C-allele; 95%-CI 0.67\u20130.90;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.001). On the other hand, the C-allele of the\n                    <jats:italic>IL6<\/jats:italic>\n                    SNP (at position-174 in the promoter; rs1800795 G\u2009&gt;\u2009C) in donor kidneys was associated with an increased risk of rejection for male organ donors (HR per C-allele 1.31; 95%-CI 1.08\u20131.58;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0006), but not female organ donors (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.33). In contrast, neither the\n                    <jats:italic>IL6<\/jats:italic>\n                    nor\n                    <jats:italic>IL6R<\/jats:italic>\n                    SNP in the recipient showed an association with renal transplant rejection. In conclusion, donor\n                    <jats:italic>IL6<\/jats:italic>\n                    and\n                    <jats:italic>IL6R<\/jats:italic>\n                    genotypes but not recipient genotypes represent an independent prognostic marker for biopsy-proven renal allograft rejection.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-95714-z","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T06:03:06Z","timestamp":1628834586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation"],"prefix":"10.1038","volume":"11","author":[{"given":"Felix","family":"Poppelaars","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Gaya da Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siawosh K.","family":"Eskandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Damman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Seelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"95714_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJM199408113310606","volume":"331","author":"M Suthanthiran","year":"1994","unstructured":"Suthanthiran, M. & Strom, T. B. Renal transplantation. N. Engl. J. Med. 331, 365\u2013376 (1994).","journal-title":"N. Engl. J. Med."},{"key":"95714_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","volume":"11","author":"KE Lamb","year":"2011","unstructured":"Lamb, K. E., Lodhi, S. & Meier-Kriesche, H.-U. Long-term renal allograft survival in the United States: A critical reappraisal. Am. J. Transpl. Off. J. Am. Soc. Transpl. Am. Soc. Transpl. Surg. 11, 450\u2013462 (2011).","journal-title":"Am. J. Transpl. Off. J. Am. Soc. Transpl. Am. Soc. Transpl. Surg."},{"key":"95714_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/2047-1440-2-S1-S1","volume":"2","author":"JR Chapman","year":"2013","unstructured":"Chapman, J. R. What are the key challenges we face in kidney transplantation today?. Transpl. Res. 2, S1 (2013).","journal-title":"Transpl. Res."},{"key":"95714_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/TP.0000000000001452","volume":"101","author":"SC Jordan","year":"2017","unstructured":"Jordan, S. C. et al. Interleukin-6, A cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: Therapeutic implications of IL-6 receptor blockade. Transplantation 101, 32\u201344 (2017).","journal-title":"Transplantation"},{"key":"95714_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","volume":"50","author":"M Murakami","year":"2019","unstructured":"Murakami, M., Kamimura, D. & Hirano, T. Pleiotropy and specificity: Insights from the interleukin 6 family of cytokines. Immunity 50, 812\u2013831 (2019).","journal-title":"Immunity"},{"key":"95714_CR6","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura, A. & Kishimoto, T. IL-6: Regulator of Treg\/Th17 balance. Eur. J. Immunol. 40, 1830\u20131835 (2010).","journal-title":"Eur. J. Immunol."},{"key":"95714_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones, S. A. & Jenkins, B. J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18, 773\u2013789 (2018).","journal-title":"Nat. Rev. Immunol."},{"issue":"Suppl 2","key":"95714_CR8","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar1916","volume":"8","author":"T Kishimoto","year":"2006","unstructured":"Kishimoto, T. Interleukin-6: Discovery of a pleiotropic cytokine. Arthritis Res. Ther. 8(Suppl 2), S2 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"95714_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"EH Choy","year":"2020","unstructured":"Choy, E. H. et al. Translating IL-6 biology into effective treatments. Nat. Rev. Rheumatol. 16, 335\u2013345 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"95714_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3389\/fimmu.2017.00405","volume":"8","author":"H Su","year":"2017","unstructured":"Su, H., Lei, C.-T. & Zhang, C. Interleukin-6 signaling pathway and its role in kidney disease: An update. Front. Immunol. 8, 405 (2017).","journal-title":"Front. Immunol."},{"key":"95714_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","volume":"268","author":"T Jostock","year":"2001","unstructured":"Jostock, T. et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268, 160\u2013167 (2001).","journal-title":"Eur. J. Biochem."},{"key":"95714_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448\u2013457 (2015).","journal-title":"Nat. Immunol."},{"key":"95714_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00007890-200102150-00022","volume":"71","author":"SE Marshall","year":"2001","unstructured":"Marshall, S. E. et al. Donor cytokine genotype influences the development of acute rejection after renal transplantation. Transplantation 71, 469\u2013476 (2001).","journal-title":"Transplantation"},{"key":"95714_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.trim.2011.10.003","volume":"26","author":"R Lv","year":"2012","unstructured":"Lv, R. et al. Association between IL-6 -174G\/C polymorphism and acute rejection of renal allograft: Evidence from a meta-analysis. Transpl. Immunol. 26, 11\u201318 (2012).","journal-title":"Transpl. Immunol."},{"key":"95714_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"A Auton","year":"2015","unstructured":"Auton, A. et al. A global reference for human genetic variation. Nature 526, 68\u201374 (2015).","journal-title":"Nature"},{"key":"95714_CR16","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2018.02664","volume":"9","author":"M Gaya da Costa","year":"2018","unstructured":"Gaya da Costa, M. et al. Age and sex-associated changes of complement activity and complement levels in a healthy caucasian population. Front. Immunol. 9, 2664 (2018).","journal-title":"Front. Immunol."},{"key":"95714_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.trre.2017.02.003","volume":"31","author":"JD Momper","year":"2017","unstructured":"Momper, J. D., Misel, M. L. & McKay, D. B. Sex differences in transplantation. Transpl. Rev. 31, 145\u2013150 (2017).","journal-title":"Transpl. Rev."},{"key":"95714_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","volume":"12","author":"J Sellar\u00e9s","year":"2012","unstructured":"Sellar\u00e9s, J. et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am. J. Transpl. 12, 388\u2013399 (2012).","journal-title":"Am. J. Transpl."},{"key":"95714_CR19","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/S0140-6736(17)31283-7","volume":"389","author":"T Wekerle","year":"2017","unstructured":"Wekerle, T., Segev, D., Lechler, R. & Oberbauer, R. Strategies for long-term preservation of kidney graft function. Lancet 389, 2152\u20132162 (2017).","journal-title":"Lancet"},{"key":"95714_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/tri.12553","volume":"28","author":"J Bamoulid","year":"2015","unstructured":"Bamoulid, J. et al. The need for minimization strategies: Current problems of immunosuppression. Transpl. Int. 28, 891\u2013900 (2015).","journal-title":"Transpl. Int."},{"key":"95714_CR21","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/ndt\/gfx365","volume":"33","author":"D Abramowicz","year":"2018","unstructured":"Abramowicz, D. et al. Recent advances in kidney transplantation: A viewpoint from the Descartes advisory board. Nephrol. Dial. Transpl. 33, 1699\u20131707 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"95714_CR22","doi-asserted-by":"crossref","unstructured":"Narazaki, M. & Kishimoto, T. The two-faced cytokine IL-6 in host defense and diseases. Int. J. Mol. Sci. 19, (2018).","DOI":"10.3390\/ijms19113528"},{"key":"95714_CR23","doi-asserted-by":"publisher","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","volume":"15","author":"EA King","year":"2019","unstructured":"King, E. A., Wade Davis, J. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489 (2019).","journal-title":"PLoS Genet."},{"key":"95714_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856\u2013860 (2015).","journal-title":"Nat. Genet."},{"key":"95714_CR25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/ng.2462","volume":"44","author":"S Eyre","year":"2012","unstructured":"Eyre, S. et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat. Genet. 44, 1336\u20131340 (2012).","journal-title":"Nat. Genet."},{"key":"95714_CR26","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","volume":"379","author":"DI Swerdlow","year":"2012","unstructured":"Swerdlow, D. I. et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet 379, 1214\u20131224 (2012).","journal-title":"Lancet"},{"key":"95714_CR27","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.1016\/S2665-9913(20)30345-3","volume":"2","author":"J Bovijn","year":"2020","unstructured":"Bovijn, J., Lindgren, C. M. & Holmes, M. V. Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19. Lancet Rheumatol. 2, e658\u2013e659 (2020).","journal-title":"Lancet Rheumatol."},{"key":"95714_CR28","doi-asserted-by":"crossref","unstructured":"Gigante, B. et al. Analysis of the role of interleukin 6 receptor haplotypes in the regulation of circulating levels of inflammatory biomarkers and risk of coronary heart disease. PLoS One 10, (2015).","DOI":"10.1371\/journal.pone.0119980"},{"key":"95714_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s10519-014-9656-8","volume":"44","author":"J Van Dongen","year":"2014","unstructured":"Van Dongen, J. et al. The contribution of the functional IL6R polymorphism rs2228145, eQTLs and other genome-wide SNPs to the heritability of plasma sIL-6R levels. Behav. Genet. 44, 368\u2013382 (2014).","journal-title":"Behav. Genet."},{"key":"95714_CR30","doi-asserted-by":"crossref","unstructured":"Ferreira, R. C. et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 9, (2013).","DOI":"10.1371\/journal.pgen.1003444"},{"key":"95714_CR31","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamacardio.2018.2287","volume":"3","author":"T Cai","year":"2018","unstructured":"Cai, T. et al. Association of interleukin 6 receptor variant with cardiovascular disease effects of interleukin 6 receptor blocking therapy: A phenome\u2014Wide association study. JAMA Cardiol. 3, 849\u2013857 (2018).","journal-title":"JAMA Cardiol."},{"key":"95714_CR32","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/j.1523-1755.2004.00936.x","volume":"66","author":"S Hoffmann","year":"2004","unstructured":"Hoffmann, S. et al. Donor genomics influence graft events: The effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney Int. 66, 1686\u20131693 (2004).","journal-title":"Kidney Int."},{"key":"95714_CR33","doi-asserted-by":"crossref","unstructured":"Ligeiro, D. et al. Impact of donor and recipient cytokine genotypes on renal allograft outcome. in Transplantation Proceedings 36, 827\u2013829 (Transplant Proc, 2004).","DOI":"10.1016\/j.transproceed.2004.03.082"},{"key":"95714_CR34","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.transproceed.2007.05.035","volume":"39","author":"A Canossi","year":"2007","unstructured":"Canossi, A. et al. Renal allograft immune response is influenced by patient and donor cytokine genotypes. Transpl. Proc. 39, 1805\u20131812 (2007).","journal-title":"Transpl. Proc."},{"key":"95714_CR35","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1097\/01.TP.0000140884.71571.BC","volume":"78","author":"NS Alakulppi","year":"2004","unstructured":"Alakulppi, N. S. et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation 78, 1422\u20131428 (2004).","journal-title":"Transplantation"},{"key":"95714_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11010-007-9694-0","volume":"311","author":"PK Manchanda","year":"2008","unstructured":"Manchanda, P. K. & Mittal, R. D. Analysis of cytokine gene polymorphisms in recipient\u2019s matched with living donors on acute rejection after renal transplantation. Mol. Cell. Biochem. 311, 57\u201365 (2008).","journal-title":"Mol. Cell. Biochem."},{"key":"95714_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijcard.2004.08.064","volume":"103","author":"R Antonicelli","year":"2005","unstructured":"Antonicelli, R. et al. The interleukin-6 -174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int. J. Cardiol. 103, 266\u2013271 (2005).","journal-title":"Int. J. Cardiol."},{"key":"95714_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11357-009-9092-5","volume":"31","author":"D Albani","year":"2009","unstructured":"Albani, D. et al. Interleukin-6 plasma level increases with age in an Italian elderly population (\u2018The Treviso Longeva\u2019-Trelong-study) with a sex-specific contribution of rs1800795 polymorphism. Age (Omaha). 31, 155\u2013162 (2009).","journal-title":"Age (Omaha)."},{"key":"95714_CR39","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1053\/euhj.2001.2678","volume":"22","author":"S Humphries","year":"2001","unstructured":"Humphries, S. The interleukin-6 \u2212174 G\/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur. Heart J. 22, 2243\u20132252 (2001).","journal-title":"Eur. Heart J."},{"key":"95714_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/08916934.2016.1261833","volume":"50","author":"SA Dar","year":"2017","unstructured":"Dar, S. A. et al. Interleukin-6-174G > C (rs1800795) polymorphism distribution and its association with rheumatoid arthritis: A case-control study and meta-analysis. Autoimmunity 50, 158\u2013169 (2017).","journal-title":"Autoimmunity"},{"key":"95714_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41021-021-00172-8","volume":"43","author":"N Salari","year":"2021","unstructured":"Salari, N. et al. The effect of polymorphisms (174G> C and 572C> G) on the Interleukin-6 gene in coronary artery disease: A systematic review and meta-analysis. Genes Environ. 43, 1 (2021).","journal-title":"Genes Environ."},{"key":"95714_CR42","first-page":"331","volume":"18","author":"TB Gonz\u00e1lez-Castro","year":"2019","unstructured":"Gonz\u00e1lez-Castro, T. B. et al. Interleukin 6 (RS1800795) gene polymorphism is associated with cardiovascular diseases: A meta-analysis of 74 studies with 86,229 subjects. EXCLI J. 18, 331\u2013355 (2019).","journal-title":"EXCLI J."},{"key":"95714_CR43","doi-asserted-by":"publisher","first-page":"14948","DOI":"10.1073\/pnas.1520861112","volume":"112","author":"EH Noss","year":"2015","unstructured":"Noss, E. H., Nguyen, H. N., Chang, S. K., Watts, G. F. M. & Brenner, M. B. Genetic polymorphism directs IL-6 expression in fibroblasts but not selected other cell types. Proc. Natl. Acad. Sci. U. S. A. 112, 14948\u201314953 (2015).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"95714_CR44","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1161\/hq0901.094280","volume":"21","author":"DJ Brull","year":"2001","unstructured":"Brull, D. J. et al. Interleukin-6 gene -174G > C and -572G > C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler. Thromb. Vasc. Biol. 21, 1458\u20131463 (2001).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"95714_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00439-007-0428-x","volume":"122","author":"JD Walston","year":"2007","unstructured":"Walston, J. D. et al. IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. Hum. Genet. 122, 485\u2013494 (2007).","journal-title":"Hum. Genet."},{"key":"95714_CR46","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/01.ATV.0000040224.49362.60","volume":"22","author":"NS Jenny","year":"2002","unstructured":"Jenny, N. S. et al. In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 22, 2066\u20132071 (2002).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"95714_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1161\/01.ATV.0000194099.65024.17","volume":"26","author":"MPS Sie","year":"2006","unstructured":"Sie, M. P. S. et al. Interleukin 6\u2013174 G\/C promoter polymorphism and risk of coronary heart disease: Results from the Rotterdam study and a meta-analysis. Arterioscler. Thromb. Vasc. Biol. 26, 212\u2013217 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"95714_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/oxfordjournals.ndt.a092278","volume":"8","author":"MHM Raasveld","year":"1993","unstructured":"Raasveld, M. H. M., Surachno, S., ten Berge, R. J. M., Weening, J. J. & Kerst, J. M. Local production of interleukin-6 during acute rejection in human renal allografts. Nephrol. Dial. Transpl. 8, 75\u201378 (1993).","journal-title":"Nephrol. Dial. Transpl."},{"key":"95714_CR49","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1097\/00007890-199705270-00023","volume":"63","author":"F Casiraghi","year":"1997","unstructured":"Casiraghi, F. et al. Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. Transplantation 63, 1508\u20131514 (1997).","journal-title":"Transplantation"},{"key":"95714_CR50","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","volume":"99","author":"AA Vo","year":"2015","unstructured":"Vo, A. A. et al. A phase I\/II trial of the interleukin-6 receptorspecific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation 99, 2356\u20132363 (2015).","journal-title":"Transplantation"},{"key":"95714_CR51","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/ajt.14228","volume":"17","author":"J Choi","year":"2017","unstructured":"Choi, J. et al. Assessment of tocilizumab (anti\u2013interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am. J. Transpl. 17, 2381\u20132389 (2017).","journal-title":"Am. J. Transpl."},{"key":"95714_CR52","doi-asserted-by":"crossref","unstructured":"Pottebaum, A. A. et al. Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients. Transplant. Direct 6, (2020).","DOI":"10.1097\/TXD.0000000000000988"},{"key":"95714_CR53","doi-asserted-by":"crossref","unstructured":"Eskandary, F. et al. Clazakizumab in late antibody-mediated rejection: Study protocol of a randomized controlled pilot trial. Trials 20, (2019).","DOI":"10.1186\/s13063-018-3158-6"},{"key":"95714_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16474","author":"J Callemeyn","year":"2020","unstructured":"Callemeyn, J. et al. Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. Am. J. Transpl. https:\/\/doi.org\/10.1111\/ajt.16474 (2020).","journal-title":"Am. J. Transpl."},{"key":"95714_CR55","doi-asserted-by":"crossref","unstructured":"Dessing, M. C. et al. Donor and recipient genetic variants in NLRP3 associate with early acute rejection following kidney transplantation. Sci. Rep. 6, (2016).","DOI":"10.1038\/srep36315"},{"key":"95714_CR56","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1600-6143.2011.03880.x","volume":"12","author":"J Damman","year":"2012","unstructured":"Damman, J. et al. Association of complement C3 gene variants with renal transplant outcome of deceased cardiac dead donor kidneys. Am. J. Transpl. 12, 660\u2013668 (2012).","journal-title":"Am. J. Transpl."},{"key":"95714_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2011.11.009","volume":"50","author":"J Damman","year":"2012","unstructured":"Damman, J. et al. Lectin complement pathway gene profile of the donor and recipient does not influence graft outcome after kidney transplantation. Mol. Immunol. 50, 1\u20138 (2012).","journal-title":"Mol. Immunol."},{"key":"95714_CR58","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1093\/bioinformatics\/btm443","volume":"23","author":"YY Teo","year":"2007","unstructured":"Teo, Y. Y. et al. A genotype calling algorithm for the Illumina BeadArray platform. Bioinformatics 23, 2741\u20132746 (2007).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95714-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95714-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95714-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:29:46Z","timestamp":1670052586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95714-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["95714"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-95714-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.17.21255669","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"assertion":[{"value":"17 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16483"}}